Kintegral Advisory LLC Has $3.35 Million Stake in Edwards Lifesciences Corporation (NYSE:EW)

Kintegral Advisory LLC lessened its stake in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 32.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 46,145 shares of the medical research company's stock after selling 22,631 shares during the period. Kintegral Advisory LLC's holdings in Edwards Lifesciences were worth $3,345,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Prosperity Consulting Group LLC grew its stake in Edwards Lifesciences by 3.6% during the fourth quarter. Prosperity Consulting Group LLC now owns 3,906 shares of the medical research company's stock worth $289,000 after buying an additional 134 shares during the period. Arlington Trust Co LLC boosted its position in shares of Edwards Lifesciences by 1.2% in the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company's stock worth $804,000 after buying an additional 135 shares during the period. Versant Capital Management Inc grew its stake in shares of Edwards Lifesciences by 9.3% in the first quarter. Versant Capital Management Inc now owns 1,698 shares of the medical research company's stock valued at $123,000 after buying an additional 145 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Edwards Lifesciences by 0.5% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company's stock valued at $2,170,000 after buying an additional 145 shares during the period. Finally, Kera Capital Partners Inc. raised its holdings in shares of Edwards Lifesciences by 5.0% during the 1st quarter. Kera Capital Partners Inc. now owns 3,090 shares of the medical research company's stock valued at $224,000 after buying an additional 148 shares during the period. Hedge funds and other institutional investors own 79.46% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on EW shares. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a research note on Tuesday, May 13th. Dbs Bank raised Edwards Lifesciences to a "hold" rating in a research report on Monday, June 2nd. Wall Street Zen cut Edwards Lifesciences from a "buy" rating to a "hold" rating in a research note on Friday, May 16th. Citigroup reissued a "buy" rating and issued a $95.00 price target (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday, May 22nd. Finally, Truist Financial dropped their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a report on Friday, April 11th. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and eleven have given a buy rating to the company's stock. According to data from MarketBeat, Edwards Lifesciences presently has an average rating of "Hold" and a consensus price target of $80.20.

Edwards Lifesciences Stock Performance

Shares of EW stock traded down $0.25 during trading hours on Friday, reaching $76.77. The stock had a trading volume of 1,679,364 shares, compared to its average volume of 5,238,956. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.45 and a quick ratio of 3.66. The firm has a 50-day simple moving average of $76.10 and a 200-day simple moving average of $73.26. The firm has a market capitalization of $45.03 billion, a PE ratio of 10.97, a price-to-earnings-growth ratio of 3.86 and a beta of 1.11. Edwards Lifesciences Corporation has a twelve month low of $58.93 and a twelve month high of $95.25.

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a net margin of 75.48% and a return on equity of 16.62%. The business had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same quarter last year, the business earned $0.66 earnings per share. The business's revenue for the quarter was up 6.2% on a year-over-year basis. As a group, equities analysts forecast that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Transactions at Edwards Lifesciences

In related news, VP Daveen Chopra sold 1,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total value of $112,620.00. Following the transaction, the vice president owned 33,496 shares of the company's stock, valued at approximately $2,514,879.68. This trade represents a 4.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the sale, the vice president owned 47,206 shares of the company's stock, valued at $3,295,450.86. The trade was a 16.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 40,648 shares of company stock valued at $2,998,866 in the last 90 days. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.